mortality/aging
|
• die at 2-4 weeks of age
|
growth/size/body
|
• dilated
|
|
• cessation of weight gain from P10 onwards
|
cardiovascular system
|
• dilated
|
|
• ECG changes under isofluorane anesthesia
|
|
• decrease in peak aortic blood flow velocity under isofluorane anesthesia
|
homeostasis/metabolism
|
• increased levels of Sod2 transcripts in hearts
|
|
• tendency toward increased total superoxide dismutase enzyme activity in hearts
• activities of aconitase, a mitochondrial enzyme highly sensitive to ROS inactivation, and of the nucleus-encoded respiratory chain complex II are not affected
|
|
• total glutathione peroxidase enzyme activity is elevated in hearts
|
|
• ECG changes under isofluorane anesthesia
• decrease in peak aortic blood flow velocity under isofluorane anesthesia
|
behavior/neurological
bradykinesia
(
J:51964
)
|
• decreased spontaneous movement from P10 onwards
|
muscle
|
• mutants exhibit a significant increase in apoptosis of cardiomyocytes
• however, no evidence of fibrosis, necrosis, or inflammatory cell infiltration is seen in the hearts
|
cellular
|
• mutants exhibit a significant increase in apoptosis of cardiomyocytes
• however, no evidence of fibrosis, necrosis, or inflammatory cell infiltration is seen in the hearts
|
|
• mosaic respiratory chain deficiency in the myocardium
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Kearns-Sayre syndrome | DOID:12934 |
OMIM:530000 |
J:51964 | |


Analysis Tools